Drug Information

Drug (ID: DG00025) and It's Reported Resistant Information

• Name: Chlorpromazine
• Synonyms: Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80
• Indication:
  In total 1 Indication(s)
  Schizophrenia [ICD-11: 6A20]; Approved; [1]
• Target: Dopamine D2 receptor (D2R); DRD2_HUMAN; [1]
• Formula: C17H19ClN2S
• IsoSMILES: CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
• InChI: 1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
• InChIKey: ZPEIMTDSQAKGNT-UHFFFAOYSA-N
• PubChem CID: 2726
• ChEBI ID: CHEBI:3647
• TTD Drug ID: D01ZII
• VARIDT ID: DR00502
• DrugBank ID: DB00477

Type(s) of Resistant Mechanism of This Drug

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-06: Mental/behavioural/neurodevelopmental disorders

Psychosis [ICD-11: 6D8Z]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: Multidrug resistance protein 1 (ABCB1) [1]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Psychosis [ICD-11: 6D8Z.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: L-MDR1 cells(Sus scrofa (Pig)); Kidney; Homo sapiens (Human); CVCL_0391
• In Vitro Model: LLC-Pk1 cells(Sus scrofa (Pig)); Kidney; Homo sapiens (Human); CVCL_0391
• Experiment for Drug Resistance: Flow cytometric assay
• Mechanism Description: The multidrug resistance transporter, P-glycoprotein (P-gp), is involved in efflux transport of several antipsychotics in the blood-brain barrier (BBB). All the antipsychotics showed various degrees of inhibitory effects on P-gp activity at concentrations ranging from 1 to 100 uM. However, risperidone and olanzapine are the most likely agents that may inhibit P-gp activity.

References

• Ref 1: Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.